[HTML][HTML] Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

B Wallden, J Storhoff, T Nielsen, N Dowidar… - BMC medical …, 2015 - Springer
B Wallden, J Storhoff, T Nielsen, N Dowidar, C Schaper, S Ferree, S Liu, S Leung, G Geiss…
BMC medical genomics, 2015Springer
Background The four intrinsic subtypes of breast cancer, defined by differential expression of
50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of
hormonal therapy and chemotherapy. Here we describe the development of Prosigna™, a
PAM50-based subtype classifier and risk model on the NanoString nCounter Dx Analysis
System intended for decentralized testing in clinical laboratories. Methods 514 formalin-
fixed, paraffin-embedded (FFPE) breast cancer patient samples were used to train …
Background
The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of hormonal therapy and chemotherapy. Here we describe the development of Prosigna™, a PAM50-based subtype classifier and risk model on the NanoString nCounter Dx Analysis System intended for decentralized testing in clinical laboratories.
Methods
514 formalin-fixed, paraffin-embedded (FFPE) breast cancer patient samples were used to train prototypical centroids for each of the intrinsic subtypes of breast cancer on the NanoString platform. Hierarchical cluster analysis of gene expression data was used to identify the prototypical centroids defined in previous PAM50 algorithm training exercises. 304 FFPE patient samples from a well annotated clinical cohort in the absence of adjuvant systemic therapy were then used to train a subtype-based risk model (i.e. Prosigna ROR score). 232 samples from a tamoxifen-treated patient cohort were used to verify the prognostic accuracy of the algorithm prior to initiating clinical validation studies.
Results
The gene expression profiles of each of the four Prosigna subtype centroids were consistent with those previously published using the PCR-based PAM50 method. Similar to previously published classifiers, tumor samples classified as Luminal A by Prosigna had the best prognosis compared to samples classified as one of the three higher-risk tumor subtypes. The Prosigna Risk of Recurrence (ROR) score model was verified to be significantly associated with prognosis as a continuous variable and to add significant information over both commonly available IHC markers and Adjuvant! Online.
Conclusions
The results from the training and verification data sets show that the FDA-cleared and CE marked Prosigna test provides an accurate estimate of the risk of distant recurrence in hormone receptor positive breast cancer and is also capable of identifying a tumor's intrinsic subtype that is consistent with the previously published PCR-based PAM50 assay. Subsequent analytical and clinical validation studies confirm the clinical accuracy and technical precision of the Prosigna PAM50 assay in a decentralized setting.
Springer